Roche-Lestienne C - Search Results

1

Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.

Richebourg S, Eclache V, Perot C, Portnoi MF, Van den Akker J, Terré C, Maareck O, Soenen V, Viguié F, Laï JL, Andrieux J, Corm S, Roche-Lestienne C; Fi-LMC Group. Richebourg S, et al. Cancer Genet Cytogenet. 2008 Apr 15;182(2):95-102. doi: 10.1016/j.cancergencyto.2008.01.005. Cancer Genet Cytogenet. 2008. PMID: 18406870

2

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Laï JL, Philippe N, Facon T, Fenaux P, Preudhomme C. Roche-Lestienne C, et al. Blood. 2002 Aug 1;100(3):1014-8. doi: 10.1182/blood.v100.3.1014. Blood. 2002. PMID: 12130516 Free article.

3

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

Roche-Lestienne C, Laï JL, Darré S, Facon T, Preudhomme C. Roche-Lestienne C, et al. N Engl J Med. 2003 May 29;348(22):2265-6. doi: 10.1056/NEJMc035089. N Engl J Med. 2003. PMID: 12773665 No abstract available.

4

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

Roche-Lestienne C, Preudhomme C. Roche-Lestienne C, et al. Semin Hematol. 2003 Apr;40(2 Suppl 2):80-2. doi: 10.1053/shem.2003.50046. Semin Hematol. 2003. PMID: 12783380 Review.

5

[Origin of resistance to Imatinib mesylate: lessons learned from this experience].

Roche-Lestienne C, Mahon FX, Preudhomme C. Roche-Lestienne C, et al. Med Sci (Paris). 2004 Dec;20(12):1125-30. doi: 10.1051/medsci/200420121125. Med Sci (Paris). 2004. PMID: 15581468 Free article. Review. French.

6

Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

Roche-Lestienne C, Darré S, Laï JL, Facon T, Guilhot J, Preudhomme C. Roche-Lestienne C, et al. Haematologica. 2005 Jan;90(1):131-3. Haematologica. 2005. PMID: 15642682

7

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.

Corm S, Biggio V, Roche-Lestienne C, Laï JL, Yakoub-Agha I, Philippe N, Nicolini FE, Facon T, Preudhomme C. Corm S, et al. Leukemia. 2005 Nov;19(11):1991-2. doi: 10.1038/sj.leu.2403931. Leukemia. 2005. PMID: 16151468 No abstract available.

8

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).

Nicolini FE, Corm S, Lê QH, Sorel N, Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, Facon T, Mahon FX, Cayuela JM, Rousselot P, Michallet M, Preudhomme C, Guilhot F, Roche-Lestienne C. Nicolini FE, et al. Leukemia. 2006 Jun;20(6):1061-6. doi: 10.1038/sj.leu.2404236. Leukemia. 2006. PMID: 16642048

9

Isolated tetrasomy 13: a fifth case report of a rare chromosome abnormality associated with poorly differentiated acute myeloid leukemia.

Roche-Lestienne C, Richebourg S, Laï JL, Andrieux J, Soenen-Cornu V, Geffroy S. Roche-Lestienne C, et al. Cancer Genet Cytogenet. 2006 Jul 15;168(2):181-2. doi: 10.1016/j.cancergencyto.2006.01.013. Cancer Genet Cytogenet. 2006. PMID: 16843114 No abstract available.

10

[Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera].

Roche-Lestienne C, Andrieux J. Roche-Lestienne C, et al. Pathol Biol (Paris). 2007 Feb;55(1):49-55. doi: 10.1016/j.patbio.2006.04.010. Epub 2006 Aug 9. Pathol Biol (Paris). 2007. PMID: 16901657 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

65 results

Search Page